Yuka Ishikawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yuka Ishikawa has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Hisahide Nishio
Faculty of Rehabilitation, Kobe Gakuin University, Kobe 651-2180, Japan
2 shared publications - Aiko Sunami
Department of Medical Laboratory Medicine, Faculty of Health Sciences, Kobe Tokiwa University, Kobe 653-0838, Japan
1 shared publication - Atsuko Takeuchi
Instrumental Analysis Center, Kobe Pharmaceutical University, 4-19-1 Motoyamakitamachi, Higashinada-ku, Kobe 658-8558, Japan
1 shared publication - Hirofumi Komaki
Translational Medical Center, National Center of Neurology and Psychiatry, Tokyo, Japan
1 shared publication - Hiromitsu Kawata
Medical Affairs Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
1 shared publication - John Robert Bach
Rutgers University New Jersey Medical School
1 shared publication
Latest Publications
- Open Access
- 11 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (22) , 10110
The Need for Variant-Specific Splicing Assessment in Developing Antisense Oligonucleotide Therapies for Duchenne Muscular Dystrophy: Lessons from the DMD c.4675−2A>G Variant
Duchenne muscular dystrophy is caused by pathogenic variants in the DMD gene. Splice-site variants can generate aberrant transcripts whose consequences cannot always be predicted by the classical reading-frame rule. Here, we characterized the c.4675−2A>G variant at the exon 34 splice acceptor site for the development of an exon-skipping therapy. A minigene analysis demonstrated that c.4675−2A>G activated a cryptic splice acceptor within exon 34 rather than inducing skipping of the entire exon, resulting in deletion of the first 7 nucleotides, a frameshift, and a premature termination codon. To restore the reading frame by promoting skipping of the entire exon 34, we used antisense oligonucleotides (ASOs) targeting distinct splice-regulatory regions. Among the ASO treatments tested, including individual ASOs and ASO combinations, A1&E4&D1 produced the highest exon exclusion and consistently promoted exon 34 skipping across the examined −2A mutant genotypes. A1&E4&D1 consists of ASOs A1, E4, and D1. A1 targeted the cryptic 3′ splice acceptor region, E4 targeted a predicted exonic splicing enhancer region, and D1 targeted the 5′ splice donor region. These findings illustrate a stepwise, variant-directed strategy in which characterization of aberrant splicing guides the design of a tailor-made ASO intervention.
- 11 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (22) , 10110
Open AccessThe Need for Variant-Specific Splicing Assessment in Developing Antisense Oligonucleotide Therapies for Duchenne Muscular Dystrophy: Lessons from the DMD c.4675−2A>G Variant
Duchenne muscular dystrophy is caused by pathogenic variants in the DMD gene. Splice-site variants can generate aberrant transcripts whose consequences cannot always be predicted by the classical reading-frame rule. Here, we characterized the c.4675−2A>G variant at the exon 34 splice acceptor site for the development of an exon-skipping therapy. A minigene analysis demonstrated that c.4675−2A>G activated a cryptic splice acceptor within exon 34 rather than inducing skipping of the entire exon, resulting in deletion of the first 7 nucleotides, a frameshift, and a premature termination codon. To restore the reading frame by promoting skipping of the entire exon 34, we used antisense oligonucleotides (ASOs) targeting distinct splice-regulatory regions. Among the ASO treatments tested, including individual ASOs and ASO combinations, A1&E4&D1 produced the highest exon exclusion and consistently promoted exon 34 skipping across the examined −2A mutant genotypes. A1&E4&D1 consists of ASOs A1, E4, and D1. A1 targeted the cryptic 3′ splice acceptor region, E4 targeted a predicted exonic splicing enhancer region, and D1 targeted the 5′ splice donor region. These findings illustrate a stepwise, variant-directed strategy in which characterization of aberrant splicing guides the design of a tailor-made ASO intervention.
- Open Access
- 18 March 2026
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 52 (2) , e70068
Myofibre Density Reveals a Critical Threshold Around Age 6 in Steroid‐Naïve Duchenne Muscular Dystrophy: A Retrospective Observational Study
Aims: In Duchenne muscular dystrophy (DMD), robust histological markers for assessing early disease progression remain elusive. We defined myofibre density ( MFD ) as the count of myofibres per square millimetre, which, in our preliminary survey of DMD muscle biopsies, steeply declined with age (Spearman's ρ : −0.85). We aimed to characterise age‐dependent MFD dynamics in early‐stage DMD. Methods: We retrospectively assessed 46 archival muscle‐biopsy slides (steroid‐naïve; collected > 40 years ago) using semi‐quantitative image analysis with digital restoration. MFD and classical histological variables were quantified. Age– MFD dynamics were modelled with segmented regression and validated using weakly informative Bayesian modelling. The primary measure was the MFD age‐breakpoint. Secondary measures included breakpoint‐detection power, age‐predictive MFD cut‐offs and behaviour of conventional variables across breakpoint‐defined age bands. Results: After quality and age‐distribution screening, 35 slides (age 1–11 years) were analysed. Segmented regression identified a breakpoint at 6.25 years (95% confidence interval [CI]: 5.08–7.42); after which MFD plateaued at lower levels. Bayesian posterior estimate was 6.37 years (95% credible interval: 5.24–7.66). A 10,000‐run Monte Carlo simulation ( n = 35) showed approximately 80% power to recapture the breakpoint within ±1.25 years. MFD cut‐offs > 596 and < 426 fibres/mm 2 corresponded to 80% and 20% probabilities of age < 6.25 years. Between the early (< 5 years) and late (≥ 7.5 years) age bands defined by the breakpoint–CI limits, myofibre‐size parameters, myofibre area and fat replacement shifted significantly. Conclusions: MFD , a simple metric, reveals a previously unrecognised phase of rapid myofibre loss lasting up to around age 6 in early‐stage DMD.
- 18 March 2026
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 52 (2) , e70068
Open AccessMyofibre Density Reveals a Critical Threshold Around Age 6 in Steroid‐Naïve Duchenne Muscular Dystrophy: A Retrospective Observational Study
Aims: In Duchenne muscular dystrophy (DMD), robust histological markers for assessing early disease progression remain elusive. We defined myofibre density ( MFD ) as the count of myofibres per square millimetre, which, in our preliminary survey of DMD muscle biopsies, steeply declined with age (Spearman's ρ : −0.85). We aimed to characterise age‐dependent MFD dynamics in early‐stage DMD. Methods: We retrospectively assessed 46 archival muscle‐biopsy slides (steroid‐naïve; collected > 40 years ago) using semi‐quantitative image analysis with digital restoration. MFD and classical histological variables were quantified. Age– MFD dynamics were modelled with segmented regression and validated using weakly informative Bayesian modelling. The primary measure was the MFD age‐breakpoint. Secondary measures included breakpoint‐detection power, age‐predictive MFD cut‐offs and behaviour of conventional variables across breakpoint‐defined age bands. Results: After quality and age‐distribution screening, 35 slides (age 1–11 years) were analysed. Segmented regression identified a breakpoint at 6.25 years (95% confidence interval [CI]: 5.08–7.42); after which MFD plateaued at lower levels. Bayesian posterior estimate was 6.37 years (95% credible interval: 5.24–7.66). A 10,000‐run Monte Carlo simulation ( n = 35) showed approximately 80% power to recapture the breakpoint within ±1.25 years. MFD cut‐offs > 596 and < 426 fibres/mm 2 corresponded to 80% and 20% probabilities of age < 6.25 years. Between the early (< 5 years) and late (≥ 7.5 years) age bands defined by the breakpoint–CI limits, myofibre‐size parameters, myofibre area and fat replacement shifted significantly. Conclusions: MFD , a simple metric, reveals a previously unrecognised phase of rapid myofibre loss lasting up to around age 6 in early‐stage DMD.
- Open Access
- 9 August 2025
- Published by Springer Nature in Neurology and Therapy
- Vol. 14 (5) , 2083-2094
Safety of Risdiplam in Japanese Patients with Spinal Muscular Atrophy: A 12‑Month Interim Analysis of a Postmarketing Surveillance Study
Risdiplam, an oral splicing modifier for the survival motor neuron-2 gene (SMN2), is approved for treating spinal muscular atrophy (SMA). While its safety and efficacy have been demonstrated in global trials, there are limited real-world data on its safety in Japanese patients with SMA. This all-case postmarketing surveillance (PMS) study aimed to assess the safety and usage patterns of risdiplam in Japan. This 12-month interim analysis is part of an ongoing PMS study that includes Japanese patients with SMA who have received risdiplam. The full observation period for this PMS is 24 months from the initiation of risdiplam treatment. Safety data, including adverse drug reactions (ADRs), were collected from case report forms (CRFs) submitted by participating healthcare facilities. ADRs were coded using the MedDRA/J classification. This study included 538 patients with SMA from 259 institutions in Japan between August 2021 and August 2022. The median age (minimum-maximum) at enrolment was 22.5 (0-83) years, and 51.5% of patients were male. SMA type II (47.2%) and III (27.9%) were the most common phenotypes. The median treatment duration was 366.0 days, and 86.1% of patients continued risdiplam treatment. ADRs were reported in 112 patients (20.8%), while serious ADRs were reported in eight patients (1.5%). The most common ADRs (classified by MedDRA System Organ Class) were gastrointestinal disorders in 86 (16.0%) patients (diarrhoea in 43 [8.0%], faeces soft in 23 [4.3%] and stomatitis in 10 [1.9%] patients). Exploratory analysis suggested that advanced age, comorbidities and concomitant medication use might be associated with an increased incidence of gastrointestinal ADRs. This 12-month interim analysis of PMS data indicated that risdiplam was well tolerated among Japanese patients with SMA, consistent with previous clinical trial findings. A comprehensive evaluation of the safety and efficacy of risdiplam will be provided in the final 24-month analysis.
- 9 August 2025
- Published by Springer Nature in Neurology and Therapy
- Vol. 14 (5) , 2083-2094
Open AccessSafety of Risdiplam in Japanese Patients with Spinal Muscular Atrophy: A 12‑Month Interim Analysis of a Postmarketing Surveillance Study
Risdiplam, an oral splicing modifier for the survival motor neuron-2 gene (SMN2), is approved for treating spinal muscular atrophy (SMA). While its safety and efficacy have been demonstrated in global trials, there are limited real-world data on its safety in Japanese patients with SMA. This all-case postmarketing surveillance (PMS) study aimed to assess the safety and usage patterns of risdiplam in Japan. This 12-month interim analysis is part of an ongoing PMS study that includes Japanese patients with SMA who have received risdiplam. The full observation period for this PMS is 24 months from the initiation of risdiplam treatment. Safety data, including adverse drug reactions (ADRs), were collected from case report forms (CRFs) submitted by participating healthcare facilities. ADRs were coded using the MedDRA/J classification. This study included 538 patients with SMA from 259 institutions in Japan between August 2021 and August 2022. The median age (minimum-maximum) at enrolment was 22.5 (0-83) years, and 51.5% of patients were male. SMA type II (47.2%) and III (27.9%) were the most common phenotypes. The median treatment duration was 366.0 days, and 86.1% of patients continued risdiplam treatment. ADRs were reported in 112 patients (20.8%), while serious ADRs were reported in eight patients (1.5%). The most common ADRs (classified by MedDRA System Organ Class) were gastrointestinal disorders in 86 (16.0%) patients (diarrhoea in 43 [8.0%], faeces soft in 23 [4.3%] and stomatitis in 10 [1.9%] patients). Exploratory analysis suggested that advanced age, comorbidities and concomitant medication use might be associated with an increased incidence of gastrointestinal ADRs. This 12-month interim analysis of PMS data indicated that risdiplam was well tolerated among Japanese patients with SMA, consistent with previous clinical trial findings. A comprehensive evaluation of the safety and efficacy of risdiplam will be provided in the final 24-month analysis.
- Open Access
- 14 October 2021
- Published by Taylor & Francis in Pulmonology
- Vol. 27 (6) , 509-517
Continuous noninvasive ventilatory support outcomes for patients with neuromuscular disease: a multicenter data collaboration
Background: Typically, patients with progressive neuromuscular disorders (NMDs) develop acute respiratory failure (ARF), are intubated, and when failing spontaneous breathing trials (SBTs) undergo a tracheotomy and receive tracheostomy mechanical ventilation (TMV). However, increasing numbers of patients use nasal noninvasive ventilation (NIV), initially for sleep and this is extended to continuous dependence (CNVS). This can be used as a strategy to assist in successful extubation . We retrospectively reviewed 19 centers offering CNVS and mechanical insufflation-exsufflation (MI-E) as an alternative to TMV. Methods: Centers with publications or presentations concerning CNVS outcomes data were pooled for amyotrophic lateral sclerosis (ALS), Duchenne muscular dystrophy (DMD), and spinal muscular atrophy type 1 (SMA1). Progression to CNVS dependence without hospitalization, duration of dependence, and extubations and decannulations to CNVS were recorded. Prolongation of life was defined by duration of CNVS dependence without ventilator free breathing ability (VFBA). Results: There were 1623 part time (<23 h/day) NVS users with ALS, DMD, and SMA1 from 19 centers in 16 countries of whom 761 (47%) were CNVS dependent for 2218 patient-years. This included: 335 ALS patients for a mean 1.2 ± 1.0 (range to 8) years each; 385 DMD patients for 5.4 ± 1.6 (range to 29) years; and 41 SMA1 patients for 5.9 ± 1.8 (range to 20) years. Thirty-five DMD and ALS TMV users were decannulated to CNVS and MI-E. At data collection 494 (65%) patients were CNVS dependent but 110 (74 of whom with bulbar ALS), had undergone tracheotomies. Conclusions: ALS, DMD, and SMA1 patients can become CNVS dependent without requiring hospitalization but CNVS cannot be used indefinitely for many patients with advanced upper motor neuron diseases.
- 14 October 2021
- Published by Taylor & Francis in Pulmonology
- Vol. 27 (6) , 509-517
Open AccessContinuous noninvasive ventilatory support outcomes for patients with neuromuscular disease: a multicenter data collaboration
Background: Typically, patients with progressive neuromuscular disorders (NMDs) develop acute respiratory failure (ARF), are intubated, and when failing spontaneous breathing trials (SBTs) undergo a tracheotomy and receive tracheostomy mechanical ventilation (TMV). However, increasing numbers of patients use nasal noninvasive ventilation (NIV), initially for sleep and this is extended to continuous dependence (CNVS). This can be used as a strategy to assist in successful extubation . We retrospectively reviewed 19 centers offering CNVS and mechanical insufflation-exsufflation (MI-E) as an alternative to TMV. Methods: Centers with publications or presentations concerning CNVS outcomes data were pooled for amyotrophic lateral sclerosis (ALS), Duchenne muscular dystrophy (DMD), and spinal muscular atrophy type 1 (SMA1). Progression to CNVS dependence without hospitalization, duration of dependence, and extubations and decannulations to CNVS were recorded. Prolongation of life was defined by duration of CNVS dependence without ventilator free breathing ability (VFBA). Results: There were 1623 part time (<23 h/day) NVS users with ALS, DMD, and SMA1 from 19 centers in 16 countries of whom 761 (47%) were CNVS dependent for 2218 patient-years. This included: 335 ALS patients for a mean 1.2 ± 1.0 (range to 8) years each; 385 DMD patients for 5.4 ± 1.6 (range to 29) years; and 41 SMA1 patients for 5.9 ± 1.8 (range to 20) years. Thirty-five DMD and ALS TMV users were decannulated to CNVS and MI-E. At data collection 494 (65%) patients were CNVS dependent but 110 (74 of whom with bulbar ALS), had undergone tracheotomies. Conclusions: ALS, DMD, and SMA1 patients can become CNVS dependent without requiring hospitalization but CNVS cannot be used indefinitely for many patients with advanced upper motor neuron diseases.